Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Dear dear me - very naive.
Iām not leading horses to water - you could Google yourself in minutes and would prevent you posting and wasting energy and sheer and utter garbage.
Good luck.
You probably also need to google valuations on medical devices, Apps, tools of similar ilk
GL in your research
If I make a device to go in a plane I make a device
This is fun.
VAL were going to go bust until share holders ousted the BOD - aka George Morris.
Prostate cancer dosing application is a medical device
Really really really?
Think you need to do alittle more homework and not Manipulate peoples opinions based on information
Thatās clearly incorrect and you know it. (Read more)
Itās easy to say MC is less than an all time high - letās pick Amazon, Google, or anything in fact yeah !!!
Ā£20 millions whereās that from ? The purchase price of a company before they rolled the product out to 1000ās of medical centres and hospitals globally including Portugals health service - yeah nice one (laughing emoji)
No clear cut product haaa ok then do you have a medical background on the time it takes for medical devices to come to market . Emoji you pick one pretty sure the ICR and CRUK are supportive Ah well your opinion is key.
You havenāt mentioned the VAL payment of Ā£6million on completion of there deal. Why not? Or Bicycle or Merck or Astellas or Tabula or Cellcentric or Lilly ???
Guess you would rather sit on and oil company which is chucking millions a day at nothing or maybe something???
Good luck
Changed the subject ?
See previous post reference commercial revenue generating deal which can be utilised globaly.
Growth Stock...
Not a straight answer ok. I just believe people should do research without being spoon fed.
Anyway for your benefit,
Tabula Rasa HealthCare, Inc. (āTRHCā) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces today it has entered into a partnership with Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Through this initiative, Physiomicsā personalized docetaxel model will be integrated into TRHCās market-leading precision dosing solution, DoseMeRxĀ®. Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.
DosemeRX as per RNS
The prostate cancer dosing application that is currently in trials to over 70 patients.
These things take years to develop- this is the answer to your question as this tech will save millions and is on the verge of signing revenue generating deal will will be realised on a monthly basis
Personally Iād expect some news pre interims IMO
History would say soā¦
Some news surely needs to be due and BIG as this is slowing bleeding to death
Email JM he will respond.
what email you trying?
Has anyone emails Suzi?
The fact you have held for x amount of time and sold literally just below the news flow and updates.
Absolutely screams someone who have very little understand if the business or the industry which it is in.
Not enough research or dialog with the company I guess.
Therefore I was merely stating good as laziness shouldnāt be rewarded.
GL anyway
Good.
2p. Roughly 75million MC haaaaaaaaaaa ouch
Glen this is very very very different to Deep matter.
Deep matter made zero revenue on its products - cash burn was extremely high - huge loss making - Richard Griffiths held massive % was sold down over years (oh and now owns about 28%)
PYC is in a completely different situation and field - so please before you make remarks please understand the businesses
Just a reminder with the VAL deal confirmation in Q1 and DoseMerx also.
Rerate on the cards hereā¦
As a reminder,
Physiomics will receive a fee (capped at Ā£6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. Eligibility for part of this fee will be conditional on completion of an agreed programme of work by Physiomics that builds on the work already carried out under the 2011 agreement. This programme of work will start on 15 February 2021 and is required to be completed by 15 November 2021. In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board.